PEAK6 Investments L.P. acquired a new position in MiMedx Group, Inc. (NASDAQ:MDXG) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 77,928 shares of the medical equipment provider’s stock, valued at approximately $983,000. PEAK6 Investments L.P. owned approximately 0.07% of MiMedx Group at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. BlueCrest Capital Management Ltd purchased a new stake in shares of MiMedx Group in the 4th quarter worth about $126,000. PVG Asset Management Corp purchased a new stake in shares of MiMedx Group in the 3rd quarter worth about $127,000. Ladenburg Thalmann Financial Services Inc. grew its position in shares of MiMedx Group by 6,262.5% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,725 shares of the medical equipment provider’s stock worth $151,000 after buying an additional 12,525 shares during the period. First Republic Investment Management Inc. purchased a new stake in shares of MiMedx Group in the 4th quarter worth about $153,000. Finally, ClariVest Asset Management LLC grew its position in shares of MiMedx Group by 81.1% in the 3rd quarter. ClariVest Asset Management LLC now owns 12,953 shares of the medical equipment provider’s stock worth $154,000 after buying an additional 5,800 shares during the period. Institutional investors and hedge funds own 80.35% of the company’s stock.
A number of analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of MiMedx Group in a research report on Thursday, March 15th. BidaskClub raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Craig Hallum reissued a “buy” rating on shares of MiMedx Group in a research report on Tuesday, February 27th. ValuEngine downgraded shares of MiMedx Group from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Finally, Lake Street Capital set a $18.00 price objective on shares of MiMedx Group and gave the company a “buy” rating in a research report on Thursday, December 14th. Four research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $14.75.
Shares of MDXG stock opened at $6.46 on Friday. MiMedx Group, Inc. has a one year low of $6.05 and a one year high of $18.25. The stock has a market cap of $769.47, a P/E ratio of 53.83, a PEG ratio of 0.90 and a beta of 1.62.
MiMedx Group announced that its Board of Directors has approved a stock buyback plan on Wednesday, December 13th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical equipment provider to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s board believes its stock is undervalued.
COPYRIGHT VIOLATION WARNING: “77,928 Shares in MiMedx Group, Inc. (MDXG) Purchased by PEAK6 Investments L.P.” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/77928-shares-in-mimedx-group-inc-mdxg-purchased-by-peak6-investments-l-p.html.
MiMedx Group Company Profile
MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.